Mohammed Haneefa Nizamudeen
- Protalix BioTherapeutics (PLX) and Secarna Pharmaceuticals will work together to develop antisense oligonucleotide treatments against several targets for rare kidney disorders.
- Secarna will utilize OligoCreator, a proprietary AI-powered oligonucleotide discovery and development platform, to design the candidates.
- Terms call for